| Item Type | Name |
|
Concept
|
Doxorubicin
|
|
Academic Article
|
Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
|
|
Academic Article
|
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
|
|
Academic Article
|
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
|
|
Academic Article
|
Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
|
|
Academic Article
|
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
|
|
Academic Article
|
Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.
|
|
Academic Article
|
Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.
|
|
Academic Article
|
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
|
|
Academic Article
|
Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
|
|
Academic Article
|
Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
|
|
Academic Article
|
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
|
|
Academic Article
|
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.
|
|
Academic Article
|
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
|
|
Academic Article
|
Adjuvant docetaxel for node-positive breast cancer.
|
|
Academic Article
|
A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer.
|
|
Academic Article
|
Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
|
|
Academic Article
|
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
|
|
Academic Article
|
Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
|
|
Academic Article
|
Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
|
|
Academic Article
|
Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.
|
|
Academic Article
|
Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.
|
|
Academic Article
|
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
|
|
Academic Article
|
Extensive cutaneous metastases of ovarian cancer after prolonged response to liposomal doxorubicin.
|
|
Academic Article
|
Extensive cutaneous metastases of ovarian cancer after prolonged response to liposomal doxorubicin
|
|
Academic Article
|
Is it equivalent? Evaluation of the clinical activity of single agent Lipodox? compared to single agent Doxil? in ovarian cancer treatment.
|
|
Academic Article
|
Equivalency challenge: Evaluation of Lipodox? as the generic equivalent for Doxil? in a human ovarian cancer orthotropic mouse model.
|
|
Academic Article
|
Metastatic gynecologic malignancies: advances in treatment and management.
|
|
Academic Article
|
GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.
|
|
Academic Article
|
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
|
|
Academic Article
|
Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer.
|
|
Academic Article
|
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
|
|
Academic Article
|
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
|
|
Academic Article
|
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
|
|
Academic Article
|
An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer.
|
|
Academic Article
|
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
|
|
Academic Article
|
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
|